Table 2.

Cancer treatment type and duration for cases and controls.

	Case, n (%)	Control, n (%)	p-value
Received prior chemotherapy	6 (54.6%)	13 (59.1%)
ICI first-line monotherapy	3 (27.3%)	3 (13.6%)
ICI first-line combination therapy	2 (18.3%)	6 (27.3%)
ICI drug
Nivolumab	2 (18.2%)	2 (9.1%)	0.9152
Durvalumab	1 (9.1%)	1 (4.5%)
Pembrolizumab	6 (54.5%)	15 (68.2%)
Atezolizumab	1 (9.1%)	2 (9.1%)
Ipilimumab + nivolumab	1 (9.1%)	2 (9.1%)
Duration of ICI therapy
<3 months	4 (36.4%)	7 (31.8%)	0.3515
3–6 months	5 (45.5%)	6 (27.3%)
6–12 months	0 (0.0%)	5 (22.7%)
>12 months	2 (18.2%)	4 (18.2%)

ICI, immune checkpoint inhibitor.